Novo Nordisk ADR shares tumble over 7% on Wall Street as long-term plan fails to impress investors

Denmark-based pharmaceutical company Novo Nordisk ADR (American Depository Receipt) shares tumbled more than 7% during the pre-market hours on the New York Stock Exchange (NYSE) on Monday, September 21, as the company’s long-term plans failed to impress investors amid the weight-loss drug race.

MarketWatch data showed that Novo Nordisk ADR shares declined 7.19% to $40.13 apiece ahead of Monday’s market opening, in comparison to $43.24 apiece at the previous equity market close.

On September 21, Novo Nordisk, in its Capital Markets Day (CMD) in London, announced the pharmaceutical company’s strategic ambitions for 2030.

At the opening bell of 9:00 am (ET), Novo Nordisk ADR shares listed on the NYSE declined more than 7% to touch an intraday low of $40.18 apiece during the trading session on September 21, compared to the previous US equity market close.

Trading volumes surged to more than 883K during the early market hours on Wall Street, triggering the sell-off on Monday’s market. On the Denmark stock exchange, the company’s Series B shares lost 7.6% during the trading hours on Sept. 21.

Novo’s growth plan

In an official filing on Monday, Novo Nordisk announced the company’s strategic plan to launch at least five drugs by the year 2030 and deliver more than $23 billion in sales pipeline by 2035.

Along with the drug launches, the pharma company also plans at least five Phase 3 programmes in obesity and diabetes, and five Phase 3 programmes in other therapy areas, according to the growth and diversification plan.

To power sustainable growth, the company aims to deliver a revenue CAGR in line with industry peers within 2026-30, scale capacity to be able to serve 10x more people with obesity on oral GLP-1, and serve more than 60 million patients globally by the year 2030.

The company’s management also seeks to maintain a broadly stable operating margin and also maintain an attractive dividend per share rate.

How have Novo Nordisk shares performed?

Novo Nordisk ADR shares listed on NYSE have lost 15% of their value in the last five years, and more than 29% in the past one-year period, according to the exchange data.

On a year-to-date basis, the stock has lost 15.5%; however, Novo shares have risen 18% in the last six months. The data further showed that Novo Nordisk ADR shares have lost 7.5% in a month and were down 0.4% in the last five sessions.

Shares of Novo surged to its 52-week high of $64.16 apiece, while the 52-week low was at $35.12 apiece.

The pharma company’s market capitalisation (m-cap) was at $191.36 billion as of the trading session on Monday, September 21, 2026.